StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
VALNValneva SE
stockpulse.co.kr
Nasdaq
$5.30▼ 0.66%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $502.1MShares out 94.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

4
  • 10.15Regular26.10.15 23:29
    6-KKey event#●●●#●●●

    Valneva SE

    Valneva SE announced that its senior management will participate in several upcoming healthcare conferences in the U.S. and Europe to meet with institutional investors. During these events, the company will discuss its key value drivers, including the regulatory outlook for its Lyme disease vaccine candidate partnered with Pfizer and overall R&D pipeline progress.…more

    $5.30-0.66%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.8Pre-market26.10.08 20:57
    6-KKey event

    Valneva SE

    The UK Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for Valneva's chikungunya vaccine, IXCHIQ, in the United Kingdom. Valneva has decided not to appeal the decision, citing minimal financial and commercial impact due to low sales in the region.…more

    $5.30-0.66%vs prev close
    View filingShare
  • 8.13Regular26.08.13 23:27
    6-KKey event

    Valneva SE

    Valneva reported total revenues of €65.8 million and product sales of €64.0 million for the first half of 2026, with a net loss of €63.3 million. The company reaffirmed its 2026 full-year product sales guidance of €135 million to €150 million and is implementing restructuring initiatives to improve cash flow. As of June 30, 2026, the company holds a cash position of €121.5 million.…more

    $5.30-0.66%vs prev close
    View filingShare

3 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.8Regular26.10.09 03:27
    #●●●

    UK Revokes Approval for Valneva's Chikungunya Vaccine

    The UK regulator has revoked the marketing authorization for Valneva's chikungunya vaccine, IXCHIQ. The company stated that the impact is minimal as it had already ceased distribution in the region.…more

    $5.30-0.66%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga